Friday, July 10, 2026

pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis

Ipsen

Ipsen is a pharma organization headquartered in Paris, FR. Primary therapeutic focus areas include Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine, Alagille Syndrome, Not applicable.

70, Rue Balard, Paris, Île-de-France 75015, FR HQ
6,584 Employees
NMPA registrant Type
Company details
Status
Public
HQ
70, Rue Balard, Paris, Île-de-France 75015, FR
Employees
6,584
Programs
27
Drugs
36
Patents
0
Clinical program

CLIN-52120-464

Phase 3 · small molecule · Episodic Migraine

CLIN-52120-464 for Episodic Migraine is a Phase 3 program (small_molecule) at Ipsen with 1 ClinicalTrials.gov record(s).

← All Ipsen projects Phase 3 small molecule active

Internal code CLIN-52120-464

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Ipsen
Phase
Phase 3
Modality
small_molecule
Indication
Episodic Migraine
Status
active
Trials
1